Indivior Pharmaceuticals (INDV) EBITDA (2024 - 2026)

Indivior Pharmaceuticals' EBITDA history runs 3 years deep, the most recent figure standing at $137.0 million for Q1 2026.

• On a quarterly basis, EBITDA rose 107.58% year-over-year to $137.0 million in Q1 2026; TTM through Mar 2026 was $333.0 million, a 1048.28% increase from a year earlier, with the FY2025 full-year figure at $262.0 million, up 589.47% from the prior year.
• EBITDA climbed to $137.0 million in Q1 2026 per INDV's latest filing, from $81.0 million in the prior quarter.
• Across five years, EBITDA topped out at $137.0 million in Q1 2026 and bottomed at -$118.0 million in Q2 2024.
• The 3-year median for EBITDA is $66.0 million (2025), against an average of $48.6 million.
• Biggest YoY gain for EBITDA was 161.02% in 2025; the steepest drop was 12.0% in 2025.
• Year by year, EBITDA stood at $46.0 million in 2024, then surged by 76.09% to $81.0 million in 2025, then surged by 69.14% to $137.0 million in 2026.
• Per Business Quant, the three latest INDV EBITDA figures stand at $137.0 million (Q1 2026), $81.0 million (Q4 2025), and $43.0 million (Q3 2025).